Evidence map›Paper›PMID 40399303›Full record

Trial reportScientific reports2025

Treatment of overactive K

Lotte Kleinendorst, Sarah E Siegelaar, Helen I Roessler, Lema Meiwand, Malou van den Boogaard, Rianne H A C M de Bruin-Bon, Kirsten F van Duinen, R Nils Planken, Elisabeth H Jaspars, Patrick M J H Kemperman and 5 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lotte KleinendorstDepartment of Human Genetics, Amsterdam UMC, Amsterdam Reproduction & Development Research Institute, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Sarah E SiegelaarDepartment of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Helen I RoesslerEmma Center for Personalized Medicine, Amsterdam UMC, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Lema MeiwandDepartment of Human Genetics, Amsterdam UMC, Amsterdam Reproduction & Development Research Institute, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Malou van den BoogaardDepartment of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Rianne H A C M de Bruin-BonDepartment of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Kirsten F van DuinenDepartment of Dermatology, Ziekenhuis Nij Smellinghe, Compagnonsplein 1, Drachten, 9202 NN, The Netherlands.
R Nils PlankenDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Elisabeth H JasparsDepartment of Pathology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Patrick M J H KempermanDepartment of Dermatology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Berto J BoumaDepartment of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Colin G NicholsDepartment of Cell Biology and Physiology, Center for the Investigation of Membrane Excitability Diseases (CIMED), Washington University, St Louis, MO, 63110, USA.
Marcel W BekkenkDepartment of Dermatology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Gijs W van HaaftenDepartment of Genetics, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
Mieke M van HaelstDepartment of Human Genetics, Amsterdam UMC, Amsterdam Reproduction & Development Research Institute, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands. M.vanhaelst@amsterdamumc.nl.

Funding

Cardiovascular potassium channels: From molecular basis to disease therapeuticsR35HL171542 · NHLBI · WASHINGTON UNIVERSITY · PI Colin G Nichols · 2024 to 2026
$3.2M
NHLBI NIH HHS R35 HL171542
6 · The paper itself

Abstract

This study explores the efficacy of glibenclamide, a K

Indexed as

CardiomegalyGlyburideHypertrichosisKATP ChannelsOsteochondrodysplasiasAdultAnimalsDisease Models, AnimalFemaleHumansMaleMiddle AgedZebrafishGlyburideKATP ChannelsCantú syndromeCardiac hypertrophyDrug repurposingHypertrichosisSulfonylurea

Identifiers

PMID40399303
PMCPMC12095479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.